Today: 17 April 2026
National Australia Bank (NAB) Stock Price Slides as Oil Shock Revives RBA Hike Bets
13 March 2026
2 mins read

National Australia Bank (NAB) Stock Price Slides as Oil Shock Revives RBA Hike Bets

SYDNEY, March 13, 2026, 09:22 AEDT

  • National Australia Bank closed out Thursday at A$46.40, slipping roughly 2% from Wednesday’s A$47.32 finish.
  • ASX 200 dropped 1.3% in Australia, with the financials index down 1.5% after Brent crude pushed past $100 a barrel.
  • NAB shifted its outlook this week, projecting rate hikes for both March and May. Markets, according to Reuters, were betting on a 75% probability of a quarter-point increase next week.

National Australia Bank Ltd shares wrapped up Thursday at A$46.40, slipping roughly 2% from Wednesday’s A$47.32. A new jolt in oil prices rattled the market, sparking a selloff in Australian bank stocks and fueling renewed speculation that the Reserve Bank of Australia could hike rates again next week.

NAB shares had recently hovered just shy of a record, buoyed by last month’s robust first-quarter update. Now, after slipping roughly 3% from the A$47.96 peak reached on Feb. 18, investors are left gauging a shifting macro landscape versus one of the sector’s standout earnings runs.

NAB’s economics team on Wednesday flagged expectations for rate hikes from the central bank in both March and May, targeting a 4.35% cash rate. Reuters noted market odds now price in a 75% chance of a 25-basis-point rise next week—a basis point equals one-hundredth of a percent. Commonwealth Bank economist Belinda Allen said “the balance of probabilities has shifted” and sees hikes on the table for both months. NAB News

Sydney’s S&P/ASX 200 dropped 1.3% on Thursday, with financials slipping 1.5%. The index has now shed over 6% for the month. Brent crude finished at $100.46 per barrel—highest mark since August 2022—after attacks on two fuel tankers in Iraqi waters sparked fresh concerns over Middle East supply.

Tim Waterer, chief market analyst at KCM Trade, pointed out that unless there’s some kind of breakthrough regarding Iran and the Strait of Hormuz, risk aversion probably sticks around—the surge in oil keeps inflation fears alive. That dynamic was all it took on Thursday to pull banks down alongside the broader market.

The RBA isn’t committing to a decision yet. Deputy Governor Andrew Hauser signaled a “genuine” policy debate is on for next week, stressing inflation remains “too high” but noting policymakers see “arguments on both sides” if concerns about weaker growth are factoring in. Reuters

The slide at NAB stands out after February’s Big Four results moved in the opposite direction. Reuters noted NAB’s first-quarter cash earnings climbed 16% to A$2.02 billion. Westpac came in ahead of profit forecasts, ANZ saw a jump in cash profit, and Commonwealth Bank delivered record first-half numbers.

NAB CEO Andrew Irvine said the bank was “well placed” for sustainable growth after the update. Citi analysts, though, described the result as a “very strong headline beat” but flagged the CET1 ratio — the capital buffer — as “the clear negative.” Reuters

Things could tip in either direction over the next few sessions. Phil O’Donaghoe, Deutsche Bank’s chief economist, is leaning toward a rate hike as his base case. Still, he flagged that “an amplification of the conflict” might force a pause. Oil prices dropping would likely ease some of the strain on bank shares, but a sharper supply shock would keep inflation worries front and center. Reuters

NAB finished Thursday at A$46.40, still short of its high from last month, as oil, inflation, and the next central-bank move have quickly overshadowed what had looked like a robust bank earnings narrative.

Stock Market Today

  • Hims & Hers Stock Rises as FDA Considers Loosening Peptide Restrictions
    April 17, 2026, 10:37 AM EDT. Hims & Hers (HIMS) shares climbed 6% in early trading Thursday, extending gains after a 13% surge Wednesday. The rally follows FDA plans to reassess the classification of seven peptides currently restricted for compounding pharmacies, signaling potential regulatory easing. Health Secretary Robert F. Kennedy Jr. announced the move to shift these peptides from a banned Category 2 status to review by the Pharmacy Compounding Advisory Committee, which could broaden regulated access and reduce black market demand. Market optimism ties to Hims & Hers' recent acquisition of a peptide manufacturing plant aimed at treatments like weight loss and muscle recovery. Despite the midday jump, HIMS remains down 23% year-to-date amid ongoing regulatory risks and previous patent disputes with drugmaker Novo Nordisk.

Latest article

XRP Price Today: XRP Climbs to $1.44 as ETF Inflows, Risk-On Mood Lift Ripple-Linked Token

XRP Price Today: XRP Climbs to $1.44 as ETF Inflows, Risk-On Mood Lift Ripple-Linked Token

17 April 2026
XRP climbed to about $1.44 in early New York trading Friday, up 2.5% in 24 hours with turnover over $4 billion, outpacing bitcoin and ether. U.S.-listed spot XRP ETFs saw $17 million in net inflows on April 15, the highest since February. Ripple announced a partnership with Kyobo Life Insurance for Korea’s first tokenised government bond settlement project. XRP remains about 60% below its all-time high.
Gold Price Today Near $4,784 as Weaker Dollar Keeps Bullion on Track for Fourth Weekly Gain

Gold Price Today Near $4,784 as Weaker Dollar Keeps Bullion on Track for Fourth Weekly Gain

17 April 2026
Gold hovered near $4,784 an ounce Friday, set for a fourth weekly gain despite easing 0.1% by 0815 GMT. A 10-day Lebanon-Israel ceasefire and possible U.S.-Iran talks kept investors watching for diplomatic progress. Indian gold imports stalled as banks await new government authorization, leaving over 5 tons stuck at customs. Spot silver rose 0.7% to $78.97, platinum held steady, and palladium slipped 0.1%.
B2Gold Corp Stock Drops Nearly 3% as Gold Prices Slide and 2026 Risks Return
Previous Story

B2Gold Corp Stock Drops Nearly 3% as Gold Prices Slide and 2026 Risks Return

IREN Stock Price Slips as $6 Billion Share-Sale Plan Tests AI Buildout
Next Story

IREN Stock Price Slips as $6 Billion Share-Sale Plan Tests AI Buildout

Go toTop